FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2254484345> ?p ?o ?g. }

• W2254484345 endingPage "46" @default.
• W2254484345 startingPage "46" @default.
• W2254484345 abstract "Background In 2012 an editorial in the British Medical Journal stated that “it can confidently be assumed that pioglitazone increases the risk of bladder cancer”.1 Yet now, the recently announced results of a 10-year study mandated by the FDA have failed to demonstrate any association between pioglitazone and bladder cancer2 and, because of its many beneficial effects on glucose homeostasis and potential cardiovascular protective effects, the place of pioglitazone in the treatment of diabetes warrants reconsideration. During pre-clinical studies, an excess of bladder cancers were found in male but not female rats treated with pioglitazone.3 Of note, these bladder cancers could be prevented by acidification of the urine which prevents pioglitazone crystal formation.4 As a result of the findings in rats, the FDA requested a 10-year study of pioglitazone in humans to assess safety with regard to bladder cancer.5 The 8-year data have been published online6 and the 10-year results recently were made public.2 The main results of this study fail to show any association between pioglitazone and risk of bladder cancer.7 Another large, recently reported study involving six populations, including 1.01 million diabetic individuals from six countries across the world, has come to the same conclusion.8 Previous studies suggesting a link between pioglitazone and bladder cancer have been re-examined.7 The link between pioglitazone and bladder cancer in many of these retrospective observational studies is likely to be explained by the fact that patients treated with pioglitazone in the various databases were different from those not treated with pioglitazone, with whom they were compared, i.e. the pioglitazone-treated patients already were at higher risk of bladder cancer from other causes.7 Importantly, major risk factors for bladder cancer, i.e. smoking and proteinuria, were not available for most of these retrospective analyses. Initial concern about a potential link between pioglitazone and bladder cancer was derived from the PROactive study, where an apparent excess of bladder cancers was observed for pioglitazone (14) versus placebo (6, p=NS).7,9-11 The PROactive study investigators concluded that, because most of the bladder cancers occurred during the first year following initiation of pioglitazone therapy, the drug could not plausibly be related to the development of bladder cancer.9 Further, the total numbers of bladder cancers (n=20) was small, making it difficult to draw any meaningful conclusion about the statistically insignificant difference between the treatment groups. It has been suggested that pioglitazone might be a tumour promoter and in this way caused the excess of bladder cancer during the first year of PROactive,12 although there is no experimental evidence to support such an effect of pioglitazone. The actual data regarding the number of months into the trial when these bladder cancer cases were diagnosed has been published: most appeared so early into the trial (two cases were diagnosed 13 and 14 days into the trial respectively, one at one month, another at three months and a fifth at four months) that they could not possibly have been related to pioglitazone treatment.10,11 Links between pioglitazone and bladder cancer in meta-analyses of randomised controlled trials depend entirely on inclusion of these bladder cancer cases in the first year of PROactive, which we now know could not have been related to pioglitazone.10,11 Lastly, and most importantly, the 6-year follow up data of PROactive have been published.13 After 6 years there were 23 cases of bladder cancer in the pioglitazone-treated group versus 22 cases in the placebo-treated group. Thus, in 2015, it is highly unlikely that there is any link between pioglitazone and bladder cancer at all in humans.7,10,11" @default.
• W2254484345 created "2016-06-24" @default.
• W2254484345 creator A5071127270 @default.
• W2254484345 creator A5073917506 @default.
• W2254484345 date "2015-06-08" @default.
• W2254484345 modified "2023-09-27" @default.
• W2254484345 title "Rehabilitation of pioglitazone" @default.
• W2254484345 cites W1959209560 @default.
• W2254484345 cites W1979369530 @default.
• W2254484345 cites W1994768261 @default.
• W2254484345 cites W2008497553 @default.
• W2254484345 cites W2029145065 @default.
• W2254484345 cites W2032972682 @default.
• W2254484345 cites W2033255112 @default.
• W2254484345 cites W2055356779 @default.
• W2254484345 cites W2058649081 @default.
• W2254484345 cites W2060716197 @default.
• W2254484345 cites W2062560800 @default.
• W2254484345 cites W2069723602 @default.
• W2254484345 cites W2080070851 @default.
• W2254484345 cites W2081043740 @default.
• W2254484345 cites W2082432305 @default.
• W2254484345 cites W2084974435 @default.
• W2254484345 cites W2101827368 @default.
• W2254484345 cites W2103930636 @default.
• W2254484345 cites W2109728760 @default.
• W2254484345 cites W2121264929 @default.
• W2254484345 cites W2131330057 @default.
• W2254484345 cites W2135729475 @default.
• W2254484345 cites W2152433455 @default.
• W2254484345 cites W2159969745 @default.
• W2254484345 cites W2165349523 @default.
• W2254484345 cites W2167634088 @default.
• W2254484345 cites W2189221254 @default.
• W2254484345 cites W71678318 @default.
• W2254484345 doi "https://doi.org/10.15277/bjdvd.2015.021" @default.
• W2254484345 hasPublicationYear "2015" @default.
• W2254484345 type Work @default.
• W2254484345 sameAs 2254484345 @default.
• W2254484345 citedByCount "8" @default.
• W2254484345 countsByYear W22544843452015 @default.
• W2254484345 countsByYear W22544843452016 @default.
• W2254484345 countsByYear W22544843452018 @default.
• W2254484345 countsByYear W22544843452019 @default.
• W2254484345 countsByYear W22544843452021 @default.
• W2254484345 crossrefType "journal-article" @default.
• W2254484345 hasAuthorship W2254484345A5071127270 @default.
• W2254484345 hasAuthorship W2254484345A5073917506 @default.
• W2254484345 hasBestOaLocation W22544843451 @default.
• W2254484345 hasConcept C134018914 @default.
• W2254484345 hasConcept C1862650 @default.
• W2254484345 hasConcept C2777180221 @default.
• W2254484345 hasConcept C2778384471 @default.
• W2254484345 hasConcept C2778818304 @default.
• W2254484345 hasConcept C555293320 @default.
• W2254484345 hasConcept C71924100 @default.
• W2254484345 hasConcept C99508421 @default.
• W2254484345 hasConceptScore W2254484345C134018914 @default.
• W2254484345 hasConceptScore W2254484345C1862650 @default.
• W2254484345 hasConceptScore W2254484345C2777180221 @default.
• W2254484345 hasConceptScore W2254484345C2778384471 @default.
• W2254484345 hasConceptScore W2254484345C2778818304 @default.
• W2254484345 hasConceptScore W2254484345C555293320 @default.
• W2254484345 hasConceptScore W2254484345C71924100 @default.
• W2254484345 hasConceptScore W2254484345C99508421 @default.
• W2254484345 hasIssue "2" @default.
• W2254484345 hasLocation W22544843451 @default.
• W2254484345 hasOpenAccess W2254484345 @default.
• W2254484345 hasPrimaryLocation W22544843451 @default.
• W2254484345 hasRelatedWork W1480486014 @default.
• W2254484345 hasRelatedWork W1563850031 @default.
• W2254484345 hasRelatedWork W1981476038 @default.
• W2254484345 hasRelatedWork W2056273836 @default.
• W2254484345 hasRelatedWork W2258092894 @default.
• W2254484345 hasRelatedWork W2378831332 @default.
• W2254484345 hasRelatedWork W2415759662 @default.
• W2254484345 hasRelatedWork W2598631186 @default.
• W2254484345 hasRelatedWork W2811207875 @default.
• W2254484345 hasRelatedWork W3036934084 @default.
• W2254484345 hasVolume "15" @default.
• W2254484345 isParatext "false" @default.
• W2254484345 isRetracted "false" @default.
• W2254484345 magId "2254484345" @default.
• W2254484345 workType "article" @default.